Susan J. Crookston

Armune BioScience, Inc. researches and develops diagnostic and prognostic tests for prostate, lung, and breast cancers that may allow physicians and patients to make more personalized treatment decisions for a better prognosis. The firm's technology is based on evidence that the immune system’s early warning signals provide critical biological insight to improve cancer detection and enhance therapeutic effectiveness. The company was founded by Eli L. Thomssen in 2008 and is headquartered in Kalamazoo, MI.

Armune BioScience, Inc. researches and develops diagnostic and prognostic tests for prostate, lung, and breast cancers that may allow physicians and patients to make more personalized treatment decisions for a better prognosis. The firm's technology is based on evidence that the immune system’s early warning signals provide critical biological insight to improve cancer detection and enhance therapeutic effectiveness. The company was founded by Eli L. Thomssen in 2008 and is headquartered in Kalamazoo, MI.

Armune BioScience, Inc. researches and develops diagnostic and prognostic tests for prostate, lung, and breast cancers that may allow physicians and patients to make more personalized treatment decisions for a better prognosis. The firm's technology is based on evidence that the immune system’s early warning signals provide critical biological insight to improve cancer detection and enhance therapeutic effectiveness. The company was founded by Eli L. Thomssen in 2008 and is headquartered in Kalamazoo, MI.

Armune BioScience, Inc. researches and develops diagnostic and prognostic tests for prostate, lung, and breast cancers that may allow physicians and patients to make more personalized treatment decisions for a better prognosis. The firm's technology is based on evidence that the immune system’s early warning signals provide critical biological insight to improve cancer detection and enhance therapeutic effectiveness. The company was founded by Eli L. Thomssen in 2008 and is headquartered in Kalamazoo, MI.

Armune BioScience, Inc. researches and develops diagnostic and prognostic tests for prostate, lung, and breast cancers that may allow physicians and patients to make more personalized treatment decisions for a better prognosis. The firm's technology is based on evidence that the immune system’s early warning signals provide critical biological insight to improve cancer detection and enhance therapeutic effectiveness. The company was founded by Eli L. Thomssen in 2008 and is headquartered in Kalamazoo, MI.